23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Stoke Therapeutics, Inc. › 2025-2026

Stoke Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Stoke Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 226Asset managers, any item
  • 1,411Fund votes
  • June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 5 items on Stoke Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 5 passed (calculated).

Dissent

Significant dissent: 1 director (27.0% against).

Notable dissent: 1 director (13.1% against); 1 say-on-pay vote (72.9% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Stoke Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Stoke Therapeutics, Inc.

These tallies are Stoke Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Stoke Therapeutics, Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: G. Clare Kahn, Ph.D. 49,722,339---- 308,6445,143,930 99.4%Passed (calculated)—
Elect Director: Adrian Krainer, Ph.D. 36,531,612---- 13,499,3715,143,930 73%Passed (calculated)—
Elect Director: Julie Anne Smith 43,500,649---- 6,530,3345,143,930 87%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 55,121,1632,03651,714 ---- 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026 36,436,27513,565,29329,415 --5,143,930 73%Passed (calculated)—

Source: Stoke Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Stoke Therapeutics, Inc. 2025-2026 meeting

226 asset managers disclosed a vote on at least one Stoke Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Adrian Krainer, Ph.D.

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD
FOR: 36,531,612WITHHELD: 13,499,371
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D.

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: Adrian Krainer, Ph.D.”): 36,531,612 for, 13,499,371 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 69 asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,113,5230 04,695,882Mixed
Vanguard4,439,8030 182,032For
BlackRock00 1,638,7760Abstain
T. Rowe Price1,366,2530 0148,194Mixed
State Street1,020,8230 01,199For
Charles Schwab437,3640 00For
Dimensional00 0208,314Withhold
Equitable7,7920 0106,186Mixed
Victory Capital1,0200 0106,340Withhold
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial37,1890 032,001Mixed
QUANTITATIVE MASTER SERIES LLC00 67,9040Abstain
Principal Exchange-Traded Funds00 061,105Withhold
ALPS ETF Trust00 046,498Withhold
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares00 036,447Withhold
Goldman Sachs6,3260 025,053Mixed
Northern Trust00 031,153Withhold
Jackson National00 31,1290Abstain
Transamerica29,0100 00For
AIG/SunAmerica00 028,651Withhold
Global X27,7060 00For
Brighthouse26,8010 0359For

Fund voting reports, all 69 managers: 8,901,787 for, 5,749,235 withheld, 1,765,985 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH00 0396,000Withhold

Institutional-manager reports, all 1 managers: 396,000 withheld.

Elect Director: G. Clare Kahn, Ph.D.

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 49,722,339WITHHELD: 308,644
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: G. Clare Kahn, Ph.D.

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: G. Clare Kahn, Ph.D.”): 49,722,339 for, 308,644 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 69 asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,809,4050 00For
Vanguard4,441,8530 10For
BlackRock1,638,7760 00For
T. Rowe Price1,366,2530 0148,194Mixed
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Dimensional208,3140 00For
Equitable113,9780 00For
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial69,1900 00For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National31,1290 00For
Transamerica29,0100 00For
AIG/SunAmerica28,6510 00For
Global X27,7060 00For
Brighthouse27,1600 00For

Fund voting reports, all 69 managers: 16,267,136 for, 149,870 withheld, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH396,0000 00For

Institutional-manager reports, all 1 managers: 396,000 for.

Elect Director: Julie Anne Smith

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 43,500,649WITHHELD: 6,530,334
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: Julie Anne Smith”): 43,500,649 for, 6,530,334 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 69 asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,131,5900 04,677,815Mixed
Vanguard4,441,8420 120For
BlackRock1,638,7760 00For
T. Rowe Price1,514,4470 00For
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Dimensional00 0208,314Withhold
Equitable86,1580 027,820Mixed
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial66,1230 03,067For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National18,6000 12,5290Mixed
Transamerica29,0100 00For
AIG/SunAmerica28,6510 00For
Global X27,7060 00For
Brighthouse27,1600 00For

Fund voting reports, all 69 managers: 11,471,689 for, 4,932,777 withheld, 12,541 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH396,0000 00For

Institutional-manager reports, all 1 managers: 396,000 for.

Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST
FOR: 36,436,275AGAINST: 13,565,293

Prior year: 91.4% for (June 3, 2025 meeting) ▼ 18.5 pts

Details: description as filed, official tally, votes by 226 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Stoke Therapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission ”): 36,436,275 for, 13,565,293 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 71 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,131,5904,677,815 00Mixed
Vanguard4,441,82727 00For
BlackRock1,638,7760 00For
T. Rowe Price1,366,253148,194 00Mixed
State Street2,0971,019,925 00Against
Charles Schwab437,3640 00For
Dimensional0208,314 00Against
Equitable86,15827,820 00Mixed
Victory Capital1,020106,340 00Against
TIAA102,5640 00For
Hartford87,7450 00For
HUSSMAN INVESTMENT TRUST082,000 00Against
Lincoln Financial6,88962,301 00Mixed
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds061,105 00Against
ALPS ETF Trust046,498 00Against
JPMorgan44,6130 00For
Putnam040,736 00Against
ProShares036,447 00Against
Goldman Sachs31,3790 00For
Northern Trust031,153 00Against
Jackson National031,129 00Against
Transamerica29,0100 00For
AIG/SunAmerica028,651 00Against
Global X27,7060 00For

Fund voting reports, all 71 managers: 9,728,127 for, 6,782,161 against, 1,676 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 169 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP5,623,5250 00For
Fidelity05,320,281 00Against
Lynx1 Capital Management LP4,109,3250 00For
Redmile Group, LLC4,077,8200 00For
BVF INC/IL2,547,5570 00For
Wellington2,467,7140 00For
T. Rowe Price1,934,764283,781 00Mixed
Polar Capital Holdings Plc02,142,374 00Against
Siren, L.L.C.1,995,3470 00For
State Street3,7771,896,367 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.1,823,5000 00For
BlackRock1,722,28214,642 00For
GEODE CAPITAL MANAGEMENT, LLC1,291,2820 00For
Invesco0701,434 00Against
Candriam S.C.A.0502,020 00Against
Charles Schwab437,3890 00For
EcoR1 Capital, LLC425,0000 00For
Vanguard418,8861,473 00For
BAKER BROS. ADVISORS LP407,9740 00For
Erste Asset Management GmbH0396,000 00Against
BAILLIE GIFFORD & CO LTD390,8990 00For
Janus Henderson0316,254 00Against
MPM BioImpact LLC282,1440 00For
Northern Trust0247,472 00Against
Granahan Investment Management, LLC0244,438 00Against

Institutional-manager reports, all 169 managers: 30,969,220 for, 13,163,016 against, 108,873 abstained, 89 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeFund totals may overlapAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 55,121,163AGAINST: 2,036

Prior year: 99.8% for (June 3, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Stoke Therapeutics, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 55,121,163 for, 2,036 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 70 asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,809,4050 00For
Vanguard4,441,8540 00For
BlackRock1,638,7760 00For
T. Rowe Price1,514,4470 00For
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Dimensional208,3140 00For
Equitable113,9780 00For
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
HUSSMAN INVESTMENT TRUST82,0000 00For
Lincoln Financial69,1900 00For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National31,1290 00For
Transamerica29,0100 00For
AIG/SunAmerica28,6510 00For
Global X27,7060 00For

Fund voting reports, all 70 managers: 16,497,331 for, 1,676 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH396,0000 00For

Institutional-manager reports, all 1 managers: 396,000 for.

Largest Stoke Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 62,240,347 shares outstanding at the time of that meeting.

Fund voting reports: top Stoke Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 9.33%
2Vanguard 7.14%
3BlackRock 2.63%
4T. Rowe Price 2.43%
5State Street 1.64%
6Charles Schwab 0.70%
7Dimensional 0.33%
8Equitable 0.18%
9Victory Capital 0.17%
10TIAA 0.16%
Institutional-manager reports: top Stoke Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 9.04%
2Fidelity 8.55%
3Lynx1 Capital Management LP 6.60%
4Redmile Group, LLC 6.55%
5BVF INC/IL 4.09%
6Wellington 3.96%
7T. Rowe Price 3.56%
8Polar Capital Holdings Plc 3.44%
9Siren, L.L.C. 3.21%
10State Street 3.05%

Reported Stoke Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Stoke Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RTW Investments, LP5,940,866 9.55%Schedule 13G, filed May 15, 2026
Entities affiliated with FMR LLC5,600,920 9.00%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock5,385,714 8.65%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)5,383,666 8.65%Form 13F, quarter ended March 31, 2026
Entities affiliated with RTW Investments, L.P.5,310,033 8.53%Proxy statement (DEF 14A), table as of March 31, 2026
Entities affiliated with Lynx1 Capital Management LP5,187,191 8.33%Proxy statement (DEF 14A), table as of March 31, 2026
Entities affiliated with Redmile Group, LLC4,375,931 7.03%Proxy statement (DEF 14A), table as of March 31, 2026
Redmile Group, LLC4,164,120 6.69%Schedule 13G, filed May 15, 2026
Morgan Stanley3,546,158 5.70%Form 13F, quarter ended March 31, 2026
Entities affiliated with Morgan Stanley & Co.3,426,739 5.51%Proxy statement (DEF 14A), table as of March 31, 2026

Percentages above are of 62,240,347 shares outstanding, as reported by Stoke Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Stoke Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 226 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,411 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 73% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Stoke Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Stoke Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Stoke Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Stoke Therapeutics (STOK) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/stoke-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.